The FDA has accepted for review Dainippon Sumitomo Pharma America’s lurasidone NDA for the treatment of acute schizophrenia. The NDA was submitted on December 30, 2009 and will receive a standard review. “We are pleased that the lurasidone NDA has been accepted for review by the FDA,” said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. “We look forward to the potential lurasidone may bring as it represents our commitment to developing...